[Preclinical evaluation of drug induced QT prolongation].
Hashimoto
Keitaro
K
keitaroh@yamanashi.ac.jp
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D027682:Cation Transport Proteins; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D051638:Ether-A-Go-Go Potassium Channels; D008133:Long QT Syndrome / Q000139:chemically induced*; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D011744:Pyrimidinones / Q000009:adverse effects; D016171:Torsades de Pointes / Q000139:chemically induced
D000889:Anti-Arrhythmia Agents; D027682:Cation Transport Proteins; D051638:Ether-A-Go-Go Potassium Channels; C092509:KCNH6 protein, human; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D011744:Pyrimidinones; C076259:nifekalant